- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arrowhead Pharmaceuticals Inc (ARWR)
Arrowhead Pharmaceuticals Inc stock price live, this page displays NASDAQ ARWR stock exchange data. View the ARWR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Arrowhead Pharmaceuticals Inc real time stock price chart below.
What Is the Arrowhead Pharmaceuticals Inc Stock Price Today?
The Arrowhead Pharmaceuticals Inc stock price today is 16.06.
What Is the Stock Symbol for Arrowhead Pharmaceuticals Inc?
The stock symbol for Arrowhead Pharmaceuticals Inc is ""ARWR.""
What Stock Exchange Does Arrowhead Pharmaceuticals Inc Trade On?
Arrowhead Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Arrowhead Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Arrowhead Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARWR quote. (ISIN: US04280A1007)
What Is the Arrowhead Pharmaceuticals Inc Stock Price Today?
The Arrowhead Pharmaceuticals Inc stock price today is 16.06.
What Is the Stock Symbol for Arrowhead Pharmaceuticals Inc?
The stock symbol for Arrowhead Pharmaceuticals Inc is ""ARWR.""
What Stock Exchange Does Arrowhead Pharmaceuticals Inc Trade On?
Arrowhead Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Arrowhead Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Arrowhead Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARWR quote. (ISIN: US04280A1007)
16.06
-0.25(-1.53%)
Closed·
After Hours
15.54-0.52(-3.24%)
·
Fair Value
An estimate of a Arrowhead Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.68
16.49
52 wk Range
9.57
27.34
ARWR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ARWR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Arrowhead Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.6816.49
52 wk Range
9.5727.34
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ARWR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Arrowhead Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
44.00
Upside
+173.97%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Arrowhead Pharmaceuticals Inc Company Profile
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals Inc SWOT Analysis
Plozasiran's Promise | Arrowhead's lead drug candidate for FCS treatment nears potential FDA approval, showcasing strong Phase 3 results and advantages over competitors |
Strategic Pivot | Explore Arrowhead's shift towards cardio-metabolic treatments, allocating 75% of R&D spending to this promising area |
Market Valuation | Despite pipeline progress, stock underperforms biotech index. Analysts view current price as attractive, with targets ranging from $42 to $73 |
Future Horizons | Delve into Arrowhead's innovative integrin-targeting approach, potentially expanding applications in muscle-related disorders and differentiating from competitors |
Arrowhead Pharmaceuticals Inc Earnings Call Summary for Q2/2025
- Q2 FY2025 EPS of $2.75, surpassing forecast of -$0.45; revenue soared to $542.7M, exceeding $127.9M expectation
- Net income of $370.4M, driven by lucrative Sarepta license agreement; stock surged 8.95% in aftermarket trading
- Cash and investments at $1.1B; strong current ratio of 6.09x indicates robust short-term liquidity
- Multiple product launches anticipated, including Flodasiran for FCS with PDUFA date set for November 18, 2025
- CEO highlights company's leadership in RNAi technology, describing it as 'the broadest and best in the field'
Last Updated: 12/05/2025, 22:58
Read Full TranscriptCompare ARWR to Peers and Sector
Metrics to compare | ARWR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARWRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −15.4x | −1.1x | −0.5x | |
PEG Ratio | −0.21 | −0.06 | 0.00 | |
Price/Book | 3.2x | 2.2x | 2.6x | |
Price / LTM Sales | 4.1x | 9.2x | 3.3x | |
Upside (Analyst Target) | 142.2% | 308.0% | 43.4% | |
Fair Value Upside | Unlock | 18.5% | 7.1% | Unlock |
Analyst Ratings
10 Buy
5 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 44.00
(+173.97% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
-1.26 / -0.86
Revenue / Forecast
27.77M / 53.90M
People Also Watch
FAQ
What Stock Exchange Does Arrowhead Pharma Trade On?
Arrowhead Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Arrowhead Pharma?
The stock symbol for Arrowhead Pharma is "ARWR."
What Is the Arrowhead Pharma Market Cap?
As of today, Arrowhead Pharma market cap is 2.21B.
What Is Arrowhead Pharma's Earnings Per Share (TTM)?
The Arrowhead Pharma EPS (TTM) is -1.14.
When Is the Next Arrowhead Pharma Earnings Date?
Arrowhead Pharma will release its next earnings report on 30 Nov 2025.
From a Technical Analysis Perspective, Is ARWR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Arrowhead Pharma Stock Split?
Arrowhead Pharma has split 2 times.
How Many Employees Does Arrowhead Pharma Have?
Arrowhead Pharma has 609 employees.
What is the current trading status of Arrowhead Pharma (ARWR)?
As of 08 Aug 2025, Arrowhead Pharma (ARWR) is trading at a price of 16.06, with a previous close of 16.31. The stock has fluctuated within a day range of 15.68 to 16.49, while its 52-week range spans from 9.57 to 27.34.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.